Background Ocrelizumab is a humanised anti‐CD20 monoclonal antibody developed for the
treatment of multiple sclerosis (MS). It was approved by the Food and Drug Administration …

With the recent successful targeting of B lymphocytes in patients with multiple sclerosis (MS),
treatment with anti-CD20 monoclonal antibodies (mAbs) may represent a promising …

Pivotal trials showed the effectiveness of the monoclonal antibody ocrelizumab in relapsing
and progressive multiple sclerosis (MS). However, data on everyday practice in MS patients …

Objective: To evaluate the effect of ocrelizumab vs interferon beta-1a (IFNβ-1a) on achieving
no evidence of disease activity (NEDA) in patients with relapsing MS over 96 weeks in two …

The success of B cell–directed therapy in patients with multiple sclerosis (MS) has been
highlighted and demonstrates the essential role these cells have in the pathogenesis of MS …

Ocrelizumab is a monoclonal anti-CD20 antibody approved for the treatment of both
relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis …

Objective Pivotal clinical trials revealed good clinical efficiency of ocrelizumab while having
a good safety profile in the management of multiple sclerosis (MS). However, real-world data …

Background. Recently, ocrelizumab (Ocrevus®) was approved for the treatment of primary
progressive multiple sclerosis (PPMS) based on data from the ORATORIO clinical trial. Real …

Background: Ocrelizumab is an approved intravenously administered anti-CD20 antibody
for multiple sclerosis (MS). Shortening the 600 mg infusion to 2 hours reduces the total site …

Background and Objectives Ocrelizumab (OCR), a humanized anti-CD20 monoclonal
antibody, is highly efficient in patients with relapsing-remitting multiple sclerosis (RR-MS) …